Puliretgene Parvec for retinitis pigmentosa

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 May 2025: Trial registered, NCT06952842
  2. 4 Aug 2025: Trial started, NCT06952842

The trials

NCT06952842: Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation

State
Under way
Phase
Phase 1 and Phase 2
People
18 planned
Started
4 Aug 2025
Primary completion
18 Jun 2030
Arms
Single arm
Results
None posted
  1. 1 May 2025: Trial registered
  2. 4 Aug 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Also known as ZVS101e, ZVS203e.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.